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The automatic implantable cardioverter-defibrillator
(A'CD) has been shown to reduce the mortality rate of
patients with malignant ventricular tachyarrhythmias.
This report describes experience with implantation of 36
automatic implantable cardioverter-defibrillators (AlP-
Band AID-BR models) in 22 persons over a 44 month
patient follow-up period (mean 19.6 months). There were
five deaths: two patients died suddenly 22and 29 months,
respectively, after their second implant, one died of
congestive heart failure, one died of respiratory failure
and one died of catheter sepsis. Although 11 (50%) of
the 22 patients never received a countershock for a ven-
tricular tachyarrhythmia and are still alive, the other
11 received one or more spontaneouscountershocks. Nine
patients (41%) experienced spurious shocks during the
follow-up period. Assuming that the first shock for pre-
sumed ventricular tachyarrhythmia prevented death, the
hypothetical cumulative survival of patients at 42 months
would have been 34 ± 14.1% in the absence of an au-
Early clinical investigation of an automatic implantable de-
fibrillator (AID) beginning in 1980 (l,2) indicated a reduc-
tion in expected mortality among implant recipients (3). This
device, developed by Mirowski et al. (1,2), was designed
to terminate ventricular fibrillation and sinusoidal ventric-
ular tachycardia. Ventricular tachyarrhythmias were de-
tected by the probability density function, which measured
the time spent by the transcardiac waveform away from the
isoelectric baseline. In 1982, two automatic implantable
cardioverter-defibrillators, the AID-B and AID-BR (4,5),
replaced their forerunner (lntec Systems, Inc.) These newer
From the Division of Cardiothoracic Surgery, Department of Surgery
and the Division of Cardiology, Department of Medicine, Montefiore Med-
ical Center, Bronx, New York.
Manuscript received March 31, 1986; revised manuscript received De-
cember 9, 1986, accepted January 7, 1987.
Address for reprints: Seymour Furman, MD, Montefiore Medical Cen-
ter, III East 2lOth Street, Bronx, New York 10467.
© 1987 by the American College of Cardiology
tomatic implantablecardioverter defibrillator rather than
the actual survival rate of 59 ± 16.8%.
The cumulative devicesurvival of the 36 AID-B units
was 92 ± 5.62% at 15 months but diminished to 37 ±
14.4% by 20 months. No unit lasted longer than 22
months. There were 12 battery depletions. The number
of shocks emitted did not influence unit longevity. The
manufacturer's elective replacement indicator is of un-
certain validity. Six units remained active 7 to 17months
after surpassing their replacement indicator.
The automatic implantable cardioverter-defibrillator
prolongs the life of many patients with otherwise in-
tractable arrhythmias. Problems remain with this early
generation device including the imprecision of its ar-
rhythmia detection system resulting in false-positive dis-
charges, the limited longevityof its battery, lack of pro-
grammability and an inadequate device follow-up system.
(J Am Coli CardioI1987;9:1349-56)
devices have added capacity to detect and treat potentially
malignant but slower (that is, nonsinusoidal) sustained ven-
tricular tachyarrhythmias found to initiate many episodes of
sudden cardiac death (6-8). The criteria for tachycardia
recognition in the AID-B model includes the modified prob-
ability density function and the preset heart rate cutoff. The
AID-BR variant uses the preset heart rate cutoff only, al-
lowing for detection of narrow complex ventricular tachy-
cardias. Further studies continue to show even better sur-
vival statistics among recipients (9,10).
This report describes our experience with implantation
of 36 automatic implantable cardioverter-defibrillators in 22
individuals over a 44 month period. Problems that remain
with this early generation cardioverter-defibrillator include
the imprecision of its arrhythmia detection system resulting
in delivery of false positive discharges, the limited longevity
of its battery, lack of programmability and an inadequate
device follow-up system.
0735-1097/87/$3.50
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magnet is removed from the unit. The AIDCHEK displays
the time it takes to charge the unit and the number of shocks
delivered by the unit (whether spontaneous or induced at
postimplantation testing). Each magnet test reduces by one
the potential number of discharges stored by the battery and
the magnet test is not recorded as a shock by the telemetry
device. By performing a magnet test, the number of dis-
charges since the previous visit could be determined and
correlated with the patient's or bystanders' report of typical
presyncopal symptoms or actual syncope. The quality and
severity of symptoms, the patient's known history of supra-
ventricular arrhythmias, recent 24 hour ambulatory record-
ings and electrocardiograms (ECGs) were used to make an
assessment of the probable rhythm causing the unit to dis-
charge when this occurred in an unmonitored setting. Al-
Figure 1. Methods of automatic cardioverter-defibrillator implan-
tation. A, By wayof a median sternotomy. Twoepicardial sensing
leads are shown on the anterior right ventricle. The anodal patch
is placed on theanterior rightventricle (RV) andthecathodal patch
on the posterolateral left ventricular (LV) wall. B, Implantation
with the generator in a left upper quadrant subcutaneous pocket.
LV = left ventricle; R = right; RA = right atrium; Sup =
superior.
Methods
Patients. Between May 1982 and January 1986, 22 pa-
tients of approximately 250 who were evaluated by pro-
grammed electrical stimulation for sustained ventricular
tachycardia or ventricular fibrillation, or both, underwent
initial implantation of an automatic implantable cardio-
verter-defibrillator. Sixteen men and six women between 38
and 76 years old (mean 57.8) received 36 devices (33 AID-
B, 3 AID-BR). Twenty had coronary artery disease (two
with associated valvular disease) and two had nonischemic
cardiomyopathy (one with mitral valve prolapse). The left
ventricular ejection fraction was significantly depressed with
a mean value of 28% (9 to 64%); it was <30% in 14 of
the 22 patients.
All our patients had sustained recurrent ventricular tachy-
arrhythmias not associated with an acute myocardial in-
farction and each patient required cardiopulmonary resus-
citation or direct current cardioversion. The tachyarrhyth-
mias in all recipients remained inducible by programmed
electrical stimulation despite multiple drug trials (3-11).
The group included four individuals who remained vulner-
able after open heart surgery (1I).
Implantation techniques. The automatic implantable
cardioverter-defibrillator system includes: 1) the 292 gen-
erator; 2) two epicardial leads (or"an endocardial bipolar
lead) for rate sensing and synchronizing the discharge to
the R wave; and 3) two epicardial patches (or alternatively,
one patch and a transvenous spring lead positioned in the
superior vena cava) for the probability density function mon-
itoring and shock delivery (Fig. 1).
The previously described standard techniques for im-
plantation were used (12-16). The operative procedure was
median sternotomy in 14, left thoracotomy in 6, left sub-
costal approach in 1 and subxiphoid approach in 1. Four
individuals had the sensing leads (or patches), or both, placed
during concurrent open heart surgery (one during coronary
artery bypass grafting; two during endocardial resection; one
during both). Currently, we prefer the two patch configu-
ration over insertion of the superior vena cava spring coil
because of the higher defibrillation thresholds with the latter
approach (17). Furthermore, at our institution placement of
the vena caval leads in the catheterization laboratory and
the patch and defibrillator in the operating room requires
two operations and breaks in sterility that are undesirable
(15).
Follow-up. All patients were followed up in our pace-
maker clinic generally every other month for the first year
after implantation and monthly thereafter. Telemetry from
the automatic implantable cardioverter-defibrillator gener-
ator to an external hand-held device called an AIDCHEK
(lntec Systems, Inc.) is initiated by placing a doughnut-
shaped magnet over the upper portion of the pulse generator
for 2 to 3 seconds. A charging cycle is initiated when the
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Figure 2. Ambulatory electrocardiogram (ECG) showing tran-
sient complete heart block with slow ventricular escape rhythm
after an appropriate automatic implantable cardioverter-defibriJ-
Jator (AID-B) discharge for ventricular tachycardia (V TACH).
The patient subsequently received an implanted permanent bipolar
pacemaker. AV = atrioventricular.
though based on soft data, a judgment was made concerning
the cause of each spontaneous discharge (either false pos-
itive discharge or discharge for presumed ventricular tachy-
arrhythmia). Although most countershocks were unmoni-
tored, seven of the nine patients with appropriate discharges
had at least one documented false-positive discharge.
Results
The total cumulative postimplantation follow-up was 431
patient-months (mean 19.6, range 1 to 44 months). Eleven
individuals have been followed up for 1 to 14 months whereas
11 have been followed up for 25 months or longer. The 10
month implantation hiatus was caused by lack of both avail-
able units for implantation and patients meeting implant
indications.
Antiarrhythmic agents have been continued by 20 of the
22 patients and 9 are concomitantly receiving amiodarone
to maximize arrhythmia control. Ten cardioverter-defibril-
lator recipients have a permanent pacemaker because of
significant underlying conduction abnormalities or brady-
arrhythmias occurring during the postshock period (Fig. 2).
Patient survival. Seventeen of the 22 patients remain
alive. The first death involved a 58 year old woman with
mitral regurgitation secondary to mitral valve prolapse and
recurrent ventricular tachycardia. After experiencing 40 dis-
charges from the AID-B unit due to both ventricular tachy-
arrhythmia and recurrent atrial fibrillation with rapid ven-
tricular response refractory to drug therapy, the patient died
5 months after implantation of congestive heart failure. Death
occurred approximately 1 month after mitral valve replace-
ment and intraoperative atrioventricular (AV) node cryoab-
lation.
The second death involved a 55 year old man who died
suddenly from presumed ventricular tachycardia/ventricular
fibrillation 37 months after his initial cardioverter-defibril-
lator implantation. His tachyarrhythmia had been inducible
after endocardial resection and he received his initial implant
during the postoperative recovery period. His initial implant
failed prematurely at 15 months because of glass insulation
corrosion of the battery feed through connectors and a sec-
ond unit was implanted. Sixteen months after implantation
of the second device he experienced his first spontaneous
discharge. A noninvasive postmortem check of the second
unit revealed that it was inert (22 months after implantation).
The patient had been awaiting a replacement (unavailable
from the manufacturer) because his implant was known to
have had a markedly elevated charge time of 27.7 seconds
I month earlier, indicative of impending depletion.
The third death occurred in a 57 year old man with severe
coronary artery disease, left ventricular dysfunction and re-
current ventricular tachycardia. This patient's initial implant
failed 20 months after implantation because of battery de-
pletion. He had received three spontaneous discharges from
his first implant. Nine months after receiving his second
implant he died suddenly from ventricular fibrillation doc-
umented by ambulance paramedics. The implanted device
appeared to have functioned appropriately but failed to de-
fibrillate.
The fourth death occurred in a 55 year old man with end-
stage coronary heart disease and recurrent ventricular tachy-
cardia and fibrillation. He had received two spontaneous
postimplantation discharges and 5 months after implantation
he died from respiratory failure due to viral pneumonia. The
fifth death occurred in a 62 year old man with end-stage
coronary artery disease and recurrent ventricular tachycar-
dia. This patient died of amiodarone toxicity and catheter
sepsis 27 months after the initial implantation. During this
interval he required two unit replacements and catheter abla-
tion of his AV node for refractory atrial arrhythmias that
caused the implantable defibrillator to discharge. This pa-
tient also received many shock discharges for ventricular
tachyarrhythmias.
Although II (50%) of the 22 patients never received a
countershock for ventricular tachyarrhythmia and are still
alive, the other II sustained one or more spontaneous dis-
charges for presumed ventricular tachyarrythmias. Assum-
ing that the first discharge for presumed ventricular tachy-
arrhythmia prevented death, the hypothetical cumulative
mortality rate without an automatic implantable cardio-
verter-defibrillator at 12 and 42 months would have been
36 ± 10.3 % and 66 ± 14. 1%, respectively, rather than
the actual rate of 14 ± 6.3% and 41 ± 16.8%, respectively
(Fig. 3). Thus, the corresponding reductions in mortality
rate at 12 months and 42 months calculate to 61 and 37%,
respectively.
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Figure 3. Cumulative actual versus hypothetical survival curves
(assuming that the firstdischarge presumed to be administered for
a ventricular tachycardia prevented death) for thedevicerecipients.
Vertical bars indicate standard deviation.
Shock delivery analysis. Although the cardioverter-de-
fibrillator did not discharge spontaneously for an arrhythmia
at all during the follow-up period in 8 (36%) of the 22
patients, 14 (64%) of the 22 experienced 144 spontaneous
discharges (range I to 40). Ten (71%) of these 14 received
four or more spontaneous discharges but almost 60% of all
spontaneous events occurred in two AID-B recipients with
frequent atrial arrhythmias. Although the cause of out-of-
hospital spontaneous discharge is frequently difficult to as-
sess, 3 (21%) of the 14 patients receiving countershocks
received false-positive discharges only. Eleven (79%) of the
14 patients received discharges for presumed ventricular
tachyarrhythmia; 5 (45%) of 11 for ventricular tachyar-
rhythmias alone and 6 (54%) for both spurious reasons as
well as for ventricular tachyarrhythmias. Thus 9 (64%) of
the 14 receiving countershocks and 9 (41%) of all 22 implant
recipients experienced inappropriate discharges with several
patients incurring multiple false-positive shocks for various
reasons. False-positive discharges were caused by atrial fi-
brillation, sinus tachycardia at a rate higher than the cutoff
rate, nonsustained ventricular tachyarrhythmias and during
permanent pacemaker magnet testing.
The mean follow-up time for the 11 patients having dis-
charges for ventricular tachyarrhythmia was 17.1 months
(range 1 to 38), whereas those not receiving countershocks
for ventricular tachyarrhythmia accrued an average of 22
months of follow-up (range 6 to 44). The first presumed
spontaneous countershocks for ventricular tachyarrhythmias
in 8 (73%) of the 11 patients occurred within 3 months after
implantation. The initial incidents in the other three recip-
ients were at 13, 21 and 31 months, respectively, after
implantation.
Device longevity. Over the 44 month period, 18 of the
36 devices were removed. Twelve units were removed for
battery depletion, one for no output at the time of implan-
tation, one for insufficient output after implantation, one for
Figure4. Cumulative survival for33cardioverter-defibrillator (AID-
B) devices.
sensing difficulties two for infection (same patient) and one
for pocket erosion.
Three devices were explanted and not replaced. One
implant recipient had a protracted clinical course. Her initial
cardioverter-defibrillator (maximal output 25 J) did not ter-
minate half of the induced episodes of ventricular fibrillation
on first discharge during postoperative electrophysiologic
testing. Given the history of multiple cardiac arrests, her
device was replaced with a higher energy unit (maximal
output 33 J). Concurrent successful AV node ablation was
performed because drug-refractory atrial fibrillation had in-
duced multiple false-positive discharges. The second device
was removed 4 months later because of Staphylococcus
epidermidis infection. Ten months after intravenous anti-
biotic therapy, after what was believed to be an appropriate
interval for wound healing, a third unit was implanted. This
device became infected 2 months later and was explanted
and not replaced. The patient is currently receiving amio-
darone. A second recipient did not receive countershocks
during 19 months of follow-up and her inert device was not
replaced. A third patient was successfully treated with cath-
eter ablation of the ectopic ventricular focus. His device
was removed 11 months later after progressive pocket ero-
sion and subsequent local infection. All three patients are
alive 5 to 15 months after explantation.
The cumulative survival of the 33 AID-B devices im-
planted was 92 ± 5.3% at 15 months but diminished to 37
± 14.4% by 20 months after implantation. No unit has
lasted longer than 22 months (Fig. 4). The number of elec-
trical discharges, that is, discharges for postimplantation
testing, spontaneous discharges and magnet tests, did not
influence device longevity for those units with all discharge
data available (Table 1). The eight units that failed at a
mean of 17 months after implantation had discharged a mean
of 26 times. The 11 units still functioning at 17 months
have discharged a mean of 25 times. Although 8 of 12
depleted generators in this series were stated by the man-
ufacturer to have corrosion of the glass insulation in the
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Table 1. Number of Discharges of Units Failing After Implantation Compared With That of
Units Still Functioning >12 Months After Implantation for Units With All Discharge
Data Available
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1 2
(f-shk) (f-rno)
45 22
29 23
15 II
31 21
6 4
34 23
31 20
16 15
Unit No.
I
2
3
4
5
6
7
8
9
10
II
No. of units
Mean
Median
SD
8
25.9
30.0
12.6
8
17.4
20.5
6.9
Sample
3 4
(nf-shk) (nf-rno)
36 19
30 19
34 19
26 17
40 22
15 14
21 16
24 16
23 13
13 13
10 16
II II
24.7 16.7
24.0 16.0
9.7 2.8
The means of samples I and 3 or 2 and 4 are not statistically significant using the paired t test. f-rno and
f-shk = number of months after implantation and number of shocks, respectively, for units failing; nf-mo and
nf-shk = number of months after implantation and number of shocks. respectively, for functioning units .
feed-through connectors (Intec Systems , Inc. , January 26,
1984, personal communication), the one generator with the
shortest survival (11 months) did not. Twenty-five units
have been implanted since January 1984 (that is, these de-
vices were reported to have no glass corrosion). Four be-
came inert 11 to 22 months (mean 18.8) after implantation,
whereas all six active generators with ~ 11 months of follow-
up time have elevated charge times. Eleven other devices
that have been followed up for :510 months remain func-
tional. Four devices were explanted for reasons unrelated
to battery depletion. Six of our patients have required two
units , whereas four individuals have had three units im-
planted.
Elective replacement indicator. Given the possible se-
rious consequences of an undetected depleted unit , the man-
ufacturer recently recommended an elective replacement in-
dicator based on the time (in seconds) taken to charge the
capacitators (Jntec Systems, Jnc., June 21 , 1985, personal
communication) . This value is roughly 1.3 times the factory-
delivered charge time and is stated to indicate approximately
90% battery depletion and 3.3 months of remaining mon-
itoring time. Elective replacement indicators ranged from
6.2 to 11.24 seconds (mean 8.2).
We assessed those generators that purportedly no longer
face early depletion because of glass insulation corrosion.
All nine of these units with ~ II months of follow-up time
have achieved their elective replacement indicator. Eight of
the nine devices did so within 9 months (range 5 to 13).
Three of these units failed 12 to 17 months after surpassing
their elective replacement indicator. The other six devices
are still functional , with two active 7 to II months after
reaching the designated charge times (Table 2). The man-
ufacturer issued an electi ve replacement indicator for one
generator with glass insulation corrosion that was still func-
tioning at that time. This device outlasted its elective re-
placement indicator by an additional 12 months. The elec-
tive replacement indicator of the manufacturer is not a reliable
predictor of remaining battery life.
Operative complications. Operative complications con-
sisted of transient venous insufficiency of the ipsilateral arm
after placement of transvenous sensing and defibrillating
leads in one patient , a persistent wound infection in one
patient eventuall y requiring removal of all device hardware
and generator pocket erosion due to persistent use of a belt
in another patient , requiring removal of the generator and
extrathoracic portion of the electrodes .
Discussion
Over the past several decades malignant ventricular ar-
rhythmias have accounted for approximately 400,000 sud-
den cardiac deaths in the United States annually . Because
ideal medical management has been fervently sought but
not found, multiple treatment modalities have emerged, in-
cluding drugs, surgery and electronic devices. The clini-
cian's assignment is to tailor the available choices to the
individual's needs, which at times require a combination of
therapies. Granted market approval by the Food and Drug
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Table 2. Charge Times of 10 Automatic Implantable Cardioverter-Defibrillators Followed Up
for 2: II Months Compared With the Manufacturer's Elective Replacement Indicator
FlU FlU Status
Patient ERI ERI Achieved After ERI After Imp, (charge time)
No, GC (s) (mo) (mo) (mo) (s)
I No 11.18 8 12 20 Inert
2 No 10,27 8 14 22 Inert
3 No 9,62 5 17 22 Inert
4 No 7.02 6 II 17 10.7
5 No 7,28 13 I 14 7,9
6 No 7.28 7 7 14 10.8
7 No 8.06 9 2 11 8.3
8 No 8.19 8 3 11 8.5
9 No 6.27 II 0 11 6.5
10 Yes 8.32 7 12 19 Inert
ERI = elective replacement indicator; FlU = follow-up; GC = glass corrosion; Imp, = implantation.
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Administration (18), the automatic implantable cardio-
verter-defibrillator is now available to physicians treating
malignant ventricular arrhythmias. Our clinical experience
with patients receiving an initial implant over the past 44
months has been similar to that of other medical centers
(9,10,19). Most recipients are in their mid-50s, have coro-
nary artery disease with impaired left ventricular function
(ejection fraction ::;30%) and face an expected annual sud-
den cardiac death rate of 17 to 43.6% (20-22). On the other
hand, Mirowski et a1. (9) report a 2% arrhythmic mortality
rate with an overall 16.6% 1 year mortality rate in 67 cardio-
verter-defibrillator recipients, which is similar to the man-
ufacturer's report (23) of a 1.9% 1 year arrhythmic mortality
rate in 209 AID-B patients. Our own experience corresponds
with these figures in that there were two deaths caused by
a ventricular arrhythmia during the 44 month interval. The
other three patients who died had received shocks for ven-
tricular tachyarrhythmias and eventually died of cardiac fail-
ure.
False-positive discharges. In our experience it appeared
that a false positive generator discharge was most often
Figure 5. Ambulatory electrocardiogram showing spontaneous
nonsustained rapid ventricular tachycardia (V TACH) with an au-
tomatic implantable cardioverter-defibrillator (AID-B) discharge
3.2 seconds later during sinus rhythm. Note the ST segment changes
after discharge.
initiated by a sinus or supraventricular tachycardia whose
rate was above the preset rate cutoff and, in the AID-B,
met the modified probability density function criteria. Un-
fortunately, false-positive discharges occur quite com-
monly. The manufacturer's summary to the Food and Drug
Administration (23) stated that 25 of 323 implant recipients
had false-positive discharges during supraventricular ar-
rhythmias although, admittedly, 104 patients had discharges
for undocumented spontaneous arrhythmias, some of which
may have been supraventricular in origin. We estimated that
9 (41%) of our 22 patients and 9 (64%) of the 14 who
received countershocks experienced false-positive dis-
charges. Patients with atrial arrhythmias had countershocks
most frequently, which resulted in needless temporary phys-
ical discomfort and possibly untoward psychologic conse-
quences. Because probability density function criteria are
not used, the "rate only" AID-BR is less capable of dis-
tinguishing supraventricular arrhythmias from true malig-
nant arrhythmias and the incidence of false-positive dis-
charges may be even higher (10).
Because the automatic implantable cardioverter-defibril-
lator currently in use is not programmable, it is crucial to
select the appropriate rate cutoff (available between 120 and
200 beats/min) before implantation, to avoid both triggering
by rapid sinus or supraventricular rhythms (for example,
atrial fibrillation) and undersensing of relatively slow ven-
tricular tachycardias. Prior clinical history, exercise stress
testing, ambulatory EeG monitoring and the programmed
electrical stimulation data aid in the choice of the appropriate
rate cutoff. Given the number of recipients with false-pos-
itive discharges despite attempts to control supraventricular
arrhythmias, additional invasive therapy may be needed short
of replacing the device. Two of our patients required AV
node ablation because rapidly conducted atrial fibrillaiton
that was refractory to multiple medications induced many
inappropriate countershocks.
Spontaneous termination of nonsustained ventricular ar-
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rhythmias may result in additional undesired discharges.
This occurs because the cardioverter-defibrillator is com-
mitted to discharge once its capacitors are fully charged,
regardless of the underlying rhythm. We and others (14,24)
have documented cases of pulse delivery during sinus rhythm
after spontaneous cessation of a ventricular tachyarrhythmia
(Fig. 5). Although direct current cardioversion-defibrillation
during sinus rhythm is unlikely to create a deleterious rhythm,
one patient was reported to have had sinus tachycardia con-
verted to ventricular tachycardia by a false-positive dis-
charge (23). Design improvement should allow for confir-
mation of the existing rhythm within I second of actual
discharge.
Interaction with pacemakers. It is now known that
patients who require pacing for concomitant brady-
arrhythmias need a bipolar system to reduce the possibility
of either false-double counting or the undersensing of in-
trinsic ventricular arrhythmias generated by larger unipolar
intracardiac pacer spikes (25-28). Yet despite bipolar pac-
ing, detrimental device interactions have been reported (29,30)
that will require management by future generation automatic
implantable cardioverter-defibrillators with pacing capabil-
ities.
Functional life of the device. Reminiscent of the early
generation pacemakers, one of the bittersweet consequences
of the automatic implantable cardioverter-defibrillator's suc-
cess has been that the patients are now outlasting the de-
vices. Investigators have claimed that the device is capable
of nearly 3 years of monitoring time or over 100 discharges,
whereas only between 4 and 9% faced early battery depletion
due to corrosion of a glass insulator in the battery feed-
through connectors (9,19). The manufacturer's data indi-
cated that the estimated survival of the AID-B is approxi-
mately 55% at 2 years with a 38% survival at the lower
95% confidence level (23). With the glass insulator corro-
sion problem eliminated from the generator as of January
1, 1984, the manufacturer projected a 96% 2 year survival
of AID-B units. However others (31) report a 16.3 ± 21.1 %
24 month AID-B survival rate. None of the devices we have
implanted, including those without glass corrosion, have
lasted longer than 22 months whether removed for battery
depletion or other complications. Forty-five percent of our
patients have required at least one generator replacement.
Longevity seems dependent on the inherent limits of the
lithium battery and the high internal energy drain of these
devices.
Elective replacement indicator. Given the limited
availability and life span of the automatic implantable car-
dioverter-defibrillator, premature removal would create un-
necessary morbidity and expense. Unfortunately, the elec-
tive replacement indicator created to avoid leaving patients
unprotected is of uncertain validity. Recently the manufac-
turer has revised the elective replacement criteria. The new
elective replacement indicator is based on the following:
1.2 times the second telemetered charge time at the 8 month
postimplantation visit (Cardiac Pacemakers, Inc., May 14,
1986, personal communication). This formula has not
undergone independent clinical evaluation. We are contin-
uing to follow the recommendation that an increase in :?: I
seconds recorded between any two consecutive magnet tests
during a single follow-up examination may imply impending
failure. Because no adequate method to determine end of
battery life has been developed, the general guidelines we
follow include bimonthly AID-B checks for the first 12
months or until the charge time reaches II seconds and
monthly visits thereafter. Each patient still needs to be judged
individually.
Patient selection. When to implant and who would most
benefit from the automatic implantable cardioverter-defi-
brillator still remains a major problem given the device's
limited durability and associated morbidity and expense (ap-
proximately $14,000 for device and leads). Fifty percent of
our patients did not experience a warranted discharge over
a mean follow-up time of 22 months (range 6 to 44). At
least 49% (33 of 68) of the Stanford cohort (10) and 67%
(35 of 52) of the Johns Hopkins group (3) did not receive
a spontaneous out-of-hospital discharge over 8.9 ± 7.7
months and 14.4 months, respectively. The manufacturer's
report (23) disclosed that as of June 15, 1984, 79% of the
323 automatic implantable defibrillators (AID) and auto-
matic implantable cardioverter-defibrillators (AID-B & AID-
BR) did not provoke a discharge for a documented ventric-
ular tachyarrhythmia and if all spontaneous arrhythmias were
included, 54% (42% AID, 62% AID-B, 54% AID-BR) of
the total population had no counters hocks within the first
12 months.
Recent clinical investigations may provide data to help
increase selectivity. For example, it has become apparent
that a significant number of programmed electrical stimu-
lation failures, defined as induction of sustained ventricular
tachyarrhythmia, treated with certain antiarrhythmic agents
will have a benign clinical course (32,33). Attempts are
currently underway to predict who will have a successful
outcome (34). In addition, patients whose tachyarrhythmia
is noninducible after endocardial resection may not require
early protection from the automatic implantable cardio-
verter-defibrillator. At our institution we find it worthwhile
to implant only the patches and epicardial sensing leads
during surgery, and to reevaluate the clinical situation at
successive intervals. On the other hand, certain candidates
with extremely depressed left ventricular function and in-
frequent but nonlocalized polymorphic ventricular tachyar-
rhythmias are better suited for a cardioverter-defibrillator
device and thereby avoid endocardial resection, which has
an operative mortality rate of 14% (35,36). Additional clin-
ical investigations are needed to determine specific guide-
lines for automatic implantable cardioverter-defibrillator lead
placement after surgery for ventricular arrhythmia (37-39).
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Conclusion. The automatic implantable cardioverter-de-
fibrillator prolongs the life of many patients with otherwise
intractable ventricular arrhythmias. Major problems exist in
this early generation device. Premature battery depletion,
unwarranted electrical discharges due to an inadequate
mechanism of arrhythmia differentiation, lack of program-
mability, a questionable elective replacement indicator and
an inadequate device follow-up system were some of the
issues addressed. Along with other modifications, future
devices will have to provide programmability of the energy
output and arrhythmia detection algorithm, an arrhythmia
memory for countershock analysis and a reliable end of life
indicator.
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